Zevra Therapeutics: Exploring Rare Disease Markets with Growth Potential and Strategic Risks.
Overview
Zevra Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for rare diseases. With key assets such as Miplyffa for NPC and Olpruva for urea cycle disorders, Zevra has established a robust pipeline. The company's strategy involves acquiring late-stage rare disease assets, pushing them through approvals, and leveraging its commercial infrastructure for distribution. Zevra's transformation over recent years has positioned it as a significant player in the orphan drug market, targeting niche areas with limited competition and high unmet needs. This has accelerated its growth trajectory while catering to underserved patient populations.